Adjuvant Chemotherapy for Stage III Gastric Adenocarcinoma After D2 Dissection
For stage III gastric adenocarcinoma after D2 lymphadenectomy, adjuvant chemotherapy with capecitabine plus oxaliplatin (CAPOX/XELOX) is the recommended standard of care, based on the CLASSIC trial demonstrating improved 3-year disease-free survival from 59% to 74% and 5-year overall survival from 69% to 78%. 1, 2
Primary Treatment Recommendation
Capecitabine plus oxaliplatin (CAPOX) should be administered for 6-8 cycles following D2 resection, as this regimen has demonstrated significant survival benefits specifically in the post-D2 dissection setting. 1 The CLASSIC trial enrolled 1,035 patients with stage II-IIIB gastric cancer after D2 dissection and showed a hazard ratio for death of 0.58 for disease-free survival. 1
Alternative Regimens for Asian Populations
If the patient is of Asian descent and S-1 is available, S-1 monotherapy for 12 months is an equally valid option, based on the ACTS-GC trial showing 5-year overall survival improvement from 61.1% to 71.7% (HR 0.669) after D2 gastrectomy. 3, 4 However, S-1 remains investigational in North America and has not been validated in Western populations. 3, 1
For stage III disease specifically, S-1 plus docetaxel demonstrates superior outcomes compared to S-1 alone, with 3-year overall survival of 77.7% versus 71.2% (HR 0.742) and should be considered the preferred regimen when treating Asian patients with stage III disease. 5, 6
Critical Context: D2 Dissection Changes the Treatment Algorithm
Postoperative chemoradiotherapy is NOT recommended after adequate D2 lymphadenectomy (≥25 lymph nodes examined, ideally >30). 1, 2 The benefit of chemoradiotherapy was established in the INT-0116 trial where 54% of patients underwent inadequate D0 dissection and only 10% had D2 dissection. 3, 1
Chemoradiotherapy should only be used when:
- D0 or D1 dissection was performed (suboptimal surgery) 1, 7
- Fewer than 14 lymph nodes were examined 1
- The patient did not receive any neoadjuvant therapy 1, 7
A meta-analysis of Asian patients after D2 dissection showed that chemoradiotherapy improved locoregional control (HR 0.53) and disease-free survival (HR 0.72) but did not significantly improve overall survival (HR 0.79, p=0.08) compared to chemotherapy alone. 8
Perioperative Chemotherapy Alternative
If the patient had NOT yet undergone surgery, perioperative chemotherapy would be the preferred approach, with 3 cycles of ECF (epirubicin, cisplatin, 5-FU) or FLOT (5-FU, leucovorin, oxaliplatin, docetaxel) before and after surgery. 9, 10 The MAGIC trial demonstrated 5-year survival improvement from 23% to 36.3% with perioperative ECF. 3, 9, 3, 10 FLOT has shown superiority with median survival of 50 months versus 35 months for ECF/ECX. 10
However, since this patient has already undergone D2 dissection, postoperative chemotherapy alone is the appropriate strategy. 1, 2
Common Pitfalls to Avoid
Do not reflexively add radiation therapy after D2 dissection - this is a common error based on extrapolating the INT-0116 trial results, which primarily benefited patients with inadequate surgery. 1 The NCCN explicitly states that "postoperative chemoradiation remains an effective and preferred treatment after D0 or D1 dissection but not after D2 dissection." 1
Ensure adequate pathologic staging - at least 14 lymph nodes must be examined, with 25 or more being optimal, to confirm true stage III disease and justify the toxicity of adjuvant chemotherapy. 9, 2, 10
Verify R0 resection status - patients with R1 resection (positive margins) may benefit from chemoradiotherapy regardless of lymphadenectomy extent. 2
Treatment Monitoring
Chemotherapy should be initiated within 4-6 weeks after surgery once the patient has adequately recovered. 3 Treatment completion rates for CAPOX are approximately 74%, with dose reductions commonly required for oxaliplatin (62% of patients) and S-1 (42% of patients). 11
The main grade 3-4 toxicity is neutropenia (32%), with peripheral neuropathy being manageable through dose adjustments. 11 Treatment should continue for the planned duration unless disease progression or unacceptable toxicity occurs.